Canaccord Financial Inc. Stock
?
Your prediction
Financial data and news for Canaccord
sharewise wants to provide you with the best news and tools for Canaccord, so we directly link to the best financial data sources.
Financials
News
FuelCell Energy Just Got a Wake-Up Call From Wall Street
Key Points
- Interested in FuelCell Energy, Inc.? Here are five stocks we like better.
- Canaccord Genuity upgraded FuelCell Energy from Hold to Buy with a $30 price target, sending shares up more
Canaccord Genuity Group Q4 Earnings Call Highlights
Key Points
- Interested in Canaccord Genuity Group Inc.? Here are five stocks we like better.
- Canaccord Genuity reported a record fiscal 2026 revenue of CAD 2.2 billion, with fourth-quarter
Americas Gold and Silver Q1 Earnings Call Highlights
Americas Gold and Silver (NYSEAMERICAN:USAS) reported what management described as a strong start to 2026, citing record consolidated silver production, sharply higher revenue and progress on
NuScale Power Stock Has 195% Upside, According to This Wall Street Analyst
It has been a rough year for NuScale Power (NYSE: SMR) investors. Since 2026 began, shares of the nuclear energy developer have fallen by roughly 40%.
One Wall Street expert, however, thinks the
NuScale Power Stock Has 107.1% Upside According to This Wall Street Analyst. Is He Right?
George Gianarikas, an analyst at Canaccord Genuity, is a big fan of NuScale Power (NYSE: SMR), one of the most popular nuclear energy stocks on the market today. This month, he reiterated his "buy"
Tesla Stock Gets Wall Street Upgrade on Robotaxi Potential
Tesla (NASDAQ: TSLA) is a stock that divides Wall Street analysts, with Piper Sandler, Canaccord Genuity, and Wedbush in the bullish camp currently, with respective price targets of $500, $450, and
Is Archer Aviation Stock Going to $13 a Share?
Archer Aviation (NYSE: ACHR) has had a bumpy ride across the first four months of 2026's trading. The electric vertical takeoff and landing (eVTOL) aircraft company's share price is down roughly 23%
Why Biohaven Stock Crushed it on Monday
Biohaven (NYSE: BHVN) stock got quite the shot in the arm as the trading week began. On Monday, an analyst initiated coverage of the clinical-stage biotech with a very bullish buy recommendation